Interferon-alpha is effective in HTLV-I-associated myelopathy
Authors:
- I. GotoIGI. Goto
- Y. ItoyamaYIY. Itoyama
- T. OkajimaTOT. Okajima
- S. WatanabeSWS. Watanabe
- Y. KurodaYKY. Kuroda
- S. ArakiSAS. Araki
- M. MoriMMM. Mori
- M. NagatakiMNM. Nagataki
- S. MatsukuraSMS. Matsukura
- T. AkamineTAT. Akamine
- M. NakagawaMNM. Nakagawa
- 1 April 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 46 (4) , 1016-1021
Abstract
A double-blind, multi-center study was performed on patients with HTLV-I-associated myelopathy (HAM) to evaluate the therapeutic effect of treatment with natural interferon-alpha (HLBI). Forty-eight HAM patients were enrolled and treated with either 0.3 MU (n equals 15), 1.0 MU (n equals 17), or 3.0 MU (n equals 16) of HLBI for 28 days. Clinical evaluation included motor dysfunction, urinary disturbances, and changes of neurologic signs. The frequency of therapeutic response judged as excellent to good 4 weeks after starting therapy and 4 weeks after completion of therapy were 7.1% (1 of 14) and 8.3% (1 of 12) in the 0.3-MU group, 23.5% (4 of 17) and 26.7% (4 of 15) for the 1.0-MU group, and 66.7% (10 of 15) and 61.5% (8 of 13) for the 3.0-MU group. The therapeutic benefit in the 3.0-MU group was significantly higher than in the 0.3-MU group. There was no significant difference in the incidence of symptomatic side effects between groups. Abnormal laboratory data were obtained for some patients in the 1.0-MU and 3.0-MU groups; however, the treatment schedule could be continued in most patients. These results suggest that HAM patients may be safely treated with HLBI 3.0 MU every day for 4 weeks with favorable clinical effects. NEUROLOGY 1996;46: 1016-1021Keywords
This publication has 8 references indexed in Scilit:
- Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitisJournal of Neuroimmunology, 1989
- CONTROLLED TRIAL OF TRANSDERMAL NICOTINE PATCH IN TOBACCO WITHDRAWALThe Lancet, 1989
- Duchenne muscular dystrophyNeurology, 1988
- HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: Comparison with adult T-cell leukemia/lymphomaAnnals of Neurology, 1988
- Simian immunodeficiency viruses and their relationship to the human immunodeficiency virusesAIDS, 1988
- Message from the editorAnnals of Neurology, 1987
- LOW-DOSE ASPIRIN PREVENTS PREGNANCY-INDUCED HYPERTENSION AND PRE-ECLAMPSIA IN ANGIOTENSIN-SENSITIVE PRIMIGRAVIDAEThe Lancet, 1986
- Type I1 complex partial seizuresNeurology, 1984